Sonnet BioTherapeutics Holdings, Inc. (SONN) is lower by Wednesday morning, with the stock declining -26.52% in pre-market trading to 1.33. SONN's short-term technical score of 14 indicates that the stock has traded less bullishly over the last month than 86% of stocks on the market. In the Biotechnology industry, which ranks 137 out of 146 industries, SONN ranks higher than 28% of stocks. Sonnet BioTherapeutics Holdings, Inc. has fallen 41.04% over the past month, closing at $2.86 on September 27. During this period of time, the stock fell as low as $2.02 and as high as $2.97. SONN has an average analyst recommendation of Strong Buy. The company has an average price target of $111.14.
News Home
Sonnet BioTherapeutics Holdings, Inc. has a Long-Term Technical rank of 69. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 31% of the market scoring higher. In the Biotechnology industry which is number 133 by this metric, SONN ranks better than 133% of stocks.
Sonnet BioTherapeutics Holdings, Inc. (SONN) is down 26.52% Wednesday In Premarket Trading
Mentioned in this article
SONN has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on SONN!